Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 6/2011

01-06-2011

Challenges in the Treatment of Gastroesophageal Junction Cancer

Author: Theodore Liakakos

Published in: World Journal of Surgery | Issue 6/2011

Login to get access

Excerpt

In contrast to gastric cancer, an increase in the incidence rate of cancer that anatomically straddles the distal esophagus and proximal stomach, called cardia or gastroesophageal junction (GEJ) cancer or adenocarcinoma of the esophagogastric junction (AEG), has being observed. Despite advances with abdominothoracic surgery, chemotherapy, radiotherapy, and more recently the anti-HER2 agent trastuzumab, prognosis remains poor. Optimal multidisciplinary treatment has been hotly debated perhaps because most phase II/III clinical trials data available have emerged by including GEJ cancer either in gastric or esophageal cancer studies. The origin, causation, biological behavior, prevention, and treatment of AEG cancer remain controversial. …
Literature
1.
Reynolds JV, Ravi N, Muldoon C et al (2010) Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg 34(12):2821–2829PubMedCrossRef
2.
Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459PubMedCrossRef
3.
GASTR IC (Global advanced/adjuvant stomach tumor research international collaboration) group, Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17):1729–1737PubMedCrossRef
4.
Bang YJ, Van Cutsem E, Feyereislova A, ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRef
5.
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 11(8):1039–1043PubMedCrossRef
6.
Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef
7.
Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann Surg Oncol 16(3):774–775CrossRef
8.
Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRef
9.
Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRef
10.
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996PubMedCrossRef
11.
Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef
12.
Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef
13.
Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef
14.
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef
15.
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef
Metadata
Title
Challenges in the Treatment of Gastroesophageal Junction Cancer
Author
Theodore Liakakos
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 6/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-0977-y

Other articles of this Issue 6/2011

World Journal of Surgery 6/2011 Go to the issue

OriginalPaper

Safety Measures During Cholecystectomy: Results of a Nationwide Survey

OriginalPaper

Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities

OriginalPaper

Pancreas Divisum: A Differentiated Surgical Approach in Symptomatic Patients

OriginalPaper

Short- and Long-Term Results of Open Versus Laparoscopic Appendectomy

OriginalPaper

Quality of Care in Humanitarian Surgery

OriginalPaper

Can Transanal Tube Placement after Anterior Resection for Rectal Carcinoma Reduce Anastomotic Leakage Rate? A Single-institution Prospective Randomized Study